This story was originally published on Sept. 29.

NEW YORK (GenomeWeb) – Despite the proliferation of next-generation sequencing panel tests, many turn up results that are difficult to interpret — uncovering a known pathogenic variant whose penetrance is not understood or revealing a variant of unknown significance, for instance.

Now, researchers are attempting to solve some of these questions for patients that receive genetic testing for hereditary cancer in a project called Participants in the Prospective Registry of MultiPlex Testing (PROMPT).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.